Stephen Krahling was a published cancer researcher when vaccine maker Merck brought him on board as a virologist in 1999. That’s when he says he found himself embroiled in an all-hands-on-deck ...

Scientist Stephen Krahling worked on a project at Merck called “Protocol 7” and was uniquely positioned to blow the whistle on what he learned.

Merck posted strong Q4 earnings, with a 7% revenue increase to $15.62 billion, beating expectations. Growth was driven by ...

Merck (MRK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

The measles outbreak is surging in West Texas, especially in under-vaccinated communities, but it’s not just coverage with ...

Drug Maker Merck expects to boost employment in India with increment in its workforce across its India sites by the end of ...

We recently published a list of the 10 Best Vaccine Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Q4 2024 Earnings Conference Call February 25, 2025 4:30 PM ETCompany ParticipantsAndrew Guggenhime - President and ...

What do you think? – Alison, Eagle Point A: Alison, we suspect that what you mean by the “pneumonia vaccination” is the pneumococcal polysaccharide vaccine that protects against 23 strains ...

Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader drug portfolio continues to perform well and is driving a strong earnings ...

Lawsuits surrounding Merck's HPV vaccine Gardasil have been piling up for years now, but they've garnered increased public attention lately after HHS Secretary Robert F. Kennedy Jr.'s links to the ...